Showing 90 of 90on this page. Filters & sort apply to loaded results; URL updates for sharing.90 of 90 on this page
KONSKIE, POLAND - July 18, 2022: Allogene Therapeutics company logo ...
In this photo illustration the Allogene Therapeutics logo seen ...
Allogene Therapeutics logo in transparent PNG format
Science - Allogene
Allogene Therapeutics Looking To Raise $272 Million In IPO - Warrior ...
Allogene Therapeutics (NASDAQ:ALLO) Upgraded to Strong-Buy at UBS Group
Allogene hi-res stock photography and images - Alamy
Allogene Therapeutics Announces Pricing of Initial Public Offering ...
Allogene therapeutics hi-res stock photography and images - Alamy
Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T ...
Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical ...
Allogene Therapeutics Jobs | Glassdoor
Sep 21, 2020 South San Francisco / CA / USA - Allogene sign at their ...
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute ...
8 Allogene Therapeutics Images, Stock Photos & Vectors | Shutterstock
Allogene Therapeutics Announces Participation in March Investor ...
Allogene Therapeutics | LinkedIn
Allogene Therapeutics, Inc. (ALLO) Stock Price, News, Quote & History ...
ALLOGENE THERAPEUTICS - Allogene Therapeutics, Inc. Trademark Registration
Our Culture - Allogene
Allogene Therapeutics is a Campus Forward Award Winner | 2022
About Us - Allogene
Company: Allogene Therapeutics
Allogene Therapeutics: Q1 Earnings Snapshot
Allogene Therapeutics Q1 2026 earnings preview
Allogene Therapeutics ends China cell therapy deal with Overland | WTAQ ...
Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still ...
Allogene Therapeutics ends China cell therapy deal with Overland | KELO-AM
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of ...
Allogene Therapeutics posts narrower-than-expected loss in Q1
Allogene Therapeutics: Q1 Earnings Snapshot | wthr.com
Allogene Therapeutics, Inc.: Allogene Therapeutics Reports First ...
Allogene Therapeutics: Q1 Earnings Snapshot | king5.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2025 Earnings Call Transcript
Allogene Therapeutics: Q1 Earnings Snapshot | thv11.com
Allogene outlines cash runway into Q1 2029 while raising 2026 operating ...
Allogene Therapeutics Q1 2026 Earnings Call Transcript - Allogene ...
Ugreen Logo PNG Vector (EPS) Free Download
Allogene publica dados promissores sobre o ALLO-329 na Nature ...
Ausblick: Allogene Therapeutics legt Zahlen zum jüngsten Quartal vor ...
Акции Allogene Therapeutics Inc (ALLO) - YouTube
How to Buy Allogene Therapeutics Stock [2026] | Invest in ALLO
Allogene Therapeutics: Clinical Progress Amid Financial Headwinds ...
Allogene Therapeutics - New Era Electric
Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive ...
Home - Allogene
Allogene Therapeutics on LinkedIn: We are excited to share that we've ...
Allogene Therapeutics on LinkedIn: Allogene's Next Generation Cell Therapy
ALLO | Allogene Therapeutics Inc. Stock Overview (U.S.: Nasdaq) | Barron's
Allogene Therapeutics Arbor Biotechnologies | Amanda An
Allogene Therapeutics on LinkedIn: Learn More About the One Allogene ...
Allogene Therapeutics Presents Data on Dagger™, a Next Generation ...
Portfolio • Vida Ventures
免疫肿瘤学公司：Allogene Therapeutics, Inc.(ALLO) | 美股之家 - 港股美股开户投资百科全书
Delegates | American Biomanufacturing Summit
24 Allogenic Therapeutics Images, Stock Photos, 3D objects, & Vectors ...
FDA Holds Allogene’s AlloCAR T Clinical Trials; Shares Crash 33%
Allogene’s CAR-T could delay or prevent cancer recurrence | STAT
MarketCap | Цена и анализ акций компаний, курс сегодня
Which companies are developing allogeneic cell therapies to provide off ...
Manufacturer Community - BSMA
Allogene: Assessing The Pipeline, Competitive Landscape, And ...
FDA grants orphan drug status to Allogene’s BCMA-targeted treatment for ...
Today, in collaboration with Servier, we announced the FDA clearance of ...
